Age-related Macular degeneration (AMD) is the leading cause of irreversible vision loss in much of the world, robbing older individuals of their sight and autonomy, yet no treatments are available for the vast majority of patients. TMi is dedicated to saving sight for patients with dry AMD.
TMi has uniquely reversed engineered its approach, finding the shortest piece of string connecting the dots between patient needs, clinical trial design, pre-clinical model development and basic biology. In doing so we have taken a remarkable path focusing on a target that differs from others, using a pre-clinical model that actually mimics disease, and developing our own complementary biomarker and new measures of disease.
Assembling a remarkable team of smart, motivated people, all working together to achieve the same goal of helping our patients.
Meet the team:
Shelly Boyd - President and Chief Scientific Officer - Translatum Medicus Inc.